Use of medicines, adherence and attitudes to medicines among persons with chronic spinal cord injury

Høgholen Helene1,2, Storhaug Anette2, Kvernød Kristin2, Kostovski Emil3,4, Viktil Kirsten K1,5, Mathiesen Liv2

1School of Pharmacy, University of Oslo, Norway
2Hospital pharmacies enterprise, South Eastern Norway.
3Sunnaas Rehabilitation Hospital, Science Department, Nesoddtangen, Norway
4Faculty of Medicine, Department of Physical Medicine and Rehabilitation, University of Oslo, Norway
5Diakonhjemmet Hospital Pharmacy, Oslo, Norway

Author to whom correspondence and offprint requests are to be sent:
Helene Høgholen, Sykehusapotekene Oslo, Kirkeveien 166, 0450 Oslo, Norway
Telephone: +4741510522
E-mail: anna.helene.hoghole@sykehusapotekene.no

No conflict of interests
**Study design:** A cross-sectional study

**Objectives:** To describe use of medicines and adherence among persons with spinal cord injury (SCI). Further, to examine the influence of pain, spasms and beliefs about medicines on adherence.

**Setting:** Sunnaas Rehabilitation Hospital, Norway.

**Methods:** Persons (≥18 years) with chronic SCI (more than 1 year post injury), using at least one drug regularly, and admitted for a follow-up stay at Sunnaas Rehabilitation Hospital were included. Participants were interviewed about their drug regimen and filled out validated self-report questionnaires: Morisky Medication Adherence Scale (MMAS-8), Beliefs about Medicines Questionnaire (BMQ), Visual Analogue Scale (VAS) for pain and modified Penn Spasm Frequency Scale (mPSFS).

**Results:** The 105 participants used in average 4.2 drugs regularly (range 1-15), and 70% reported high or moderate adherence to their treatment. Of the 39 participants using oral spasmolytics, 74% reported high or moderate adherence to these drugs. A total of 97% of the participants reported high perceptions of necessity to their treatment and 54% reported a high level of concern.

**Conclusions:** The persons with SCI included in this study used in average the same number of regular drugs compared to persons with other chronic conditions. Regardless of high overall adherence, the participants were more concerned about their medicines compared to other patient groups. Further studies are required for understanding adherence and attitudes toward medicines in this population, especially to help the persons with chronic SCI feel safe about their drug regimen.

**Keywords:** spinal cord injury; adherence; oral spasmolytic drugs; beliefs about medicines;
Introduction

A spinal cord injury (SCI) can, in addition to loss of sensibility and motor function, affect most body systems, causing neuropathic pain, spasticity and cardiovascular-, bowel- and bladder-complications, all of which can result in a complex medication regimen (1-3). This often implies a challenge with regard to adherence (4).

Adherence is described by World Health Organization (WHO) as “the extent to which a person’s behavior – taking medication, following a diet, and/or executing lifestyle changes, corresponds with agreed recommendations from a health care provider” (4). There are several factors that can have an impact on adherence. A person can intentionally be non-adherent because of personal beliefs or experience. One can also be unintentionally non-adherent by forgetting to take their medicine or because of language issues (5). It is known that approximately 50% of persons with chronic conditions are non-adherent to their long-term therapies (4). Non-adherence can have a negative impact on the health benefit of a medication regimen and contribute to increased morbidity and mortality, and increased health care costs (4).

There is limited knowledge about the extent of use of medicines and also the adherence and attitudes to medicines among persons with chronic SCI (>1 year post injury (6)). To our knowledge there is only one previous study examining adherence to oral spasmolytic drugs among persons with SCI (7).

A better understanding of these challenges could help to customize and adapt counselling and level of assistance with medications to the person’s needs. The main objectives of this study were to describe the medication use in the population of persons with chronic SCI, and to examine adherence to regular medicines, and to oral spasmolytic drugs in particular. Our
secondary objective was to examine if pain, spasms and beliefs about medicines are associated with adherence.

Methods

Participants

The study was performed at the Department for follow-up at Sunnaas Rehabilitation Hospital, Nesoddtangen, Norway. There are approximately 1500-2500 persons living with SCI in Norway and Sunnaas Rehabilitation Hospital is one of three hospitals in Norway offering rehabilitation to these persons (8). Sunnaas is also the country’s largest specialized hospital in physical medicine and rehabilitation with a catchment area of about 2.9 million people (55% of the Norwegian population). In addition to its regional function, Sunnaas also has a national lifetime healthcare responsibility for all persons with SCI in Norway. Follow-up stays are voluntary, and are usually from 2 days up to several weeks of duration.

Participants over 18 years, with chronic SCI, i.e. at least one year post injury, using at least one drug regularly and being admitted for a follow-up stay between August 2015 and January 2016 were included. Participants already included were not included again if they were readmitted in the study period. Participants were excluded if they did not have adequate knowledge of Norwegian language to be able to complete the questionnaires used in the study.

Measures

A modified form based on the validated method for Integrated Medicines Management (IMM) was used for collecting information about the participants’ medication regimen (9). The modified form was tested in a pilot study with 5 participants, but not formally validated. In the first part of the form, participants were asked to provide information about which medicines they used regularly and which they used on demand and at which dosage. The
medications were registered according to the Anatomical Therapeutic Chemical (ATC) classification (10). Furthermore they reported use of spasmolytic drugs (either baclofen or tizanidine), the duration of treatment for all their medicines and if they needed assistance in taking them, and whether the medicines were prescribed by a general practitioner (GP) or a specialist. The second part of the form focused on follow-up questions regarding adherence and had open end questions about the participants experience with their medicine use.

Adherence was measured with the Morisky Medication Adherence Scale (MMAS-8) (11-13). The validated Norwegian translation of MMAS-8 and permissions to use the scale in this study was provided by Prof. Donald E. Morisky. The scale contains 8 questions assessing medication taking behavior and other aspects around adherence. Two MMAS-8 scales were used in this study, one to measure adherence to all the participants regularly used drugs and one to measure adherence to spasmolytic drugs, i.e. baclofen and tizanidine.

Beliefs about Medicines Questionnaire (BMQ) (14) consists of two sections, BMQ-Specific, which assess beliefs about necessity and concern for personal medicines, and BMQ-General, which assesses general beliefs about overuse and harm of medicines. All the questions in the BMQ-Specific and the BMQ-General are of the 5-point Likert-scale (14). The total score was divided with the amount of statements in the subscales to get a mean score. Higher scores represented higher level of agreement in the dimensions measured by the different subscales. In addition, the scores from the necessity and concern subscale were presented by dichotomizing the participants into high/low necessity and high/low concern based on whether they scored over or below the midpoint for the BMQ-Necessity and BMQ-Concern subscale. Based on these dichotomized scores the participants were then categorized into 4 different groups: Accepting (high necessity and low concern), Ambivalent (high necessity and high concern), Indifferent (low necessity and low concern) and Sceptical (low necessity and high concern) (14).
In addition, the participants were asked to provide information about the degree of pain and the spasticity they were experiencing, to see if these two variables could be associated with adherence. Pain was measured with Visual Analogue Scale (VAS) (15). The score was announced in millimeters (0-100 mm) and was divided in three different levels of pain according to an article by Collins et al published in Pain (1997), and predetermined in the protocol: mild pain (score under 30 mm), moderate pain (score between 30 mm and 54 mm) and severe pain (score over 54 mm) (16). Participants in this study were asked to fill out two separate VAS, one for the level of pain they were experiencing at the point of the interview and another one to measure pain level 14 days before the interview.

Frequency and severity of spasms were measured by modified Penn Spasm Frequency Scale (mPSFS) (17). mPSFS consists of two scales, where the first one is a 5-point scale for assessing the frequency of spasticity and the second scale a 3-point scale for assessing the severity of spasticity (17).

Procedure

Potential participants were identified by the study pharmacist or a nurse. All participants provided written, informed consent before being included in the study.

The following data was provided from the medical records for all participants before the interview: age, gender, cause and type of SCI (neurological level, traumatic or atraumatic, tetraplegia or paraplegia, complete or incomplete), American Spinal Injury Association Impairment Scale (AIS) grade (18), time since injury (years), relevant medical history and time of their last admission to Sunnaas Rehabilitation Hospital.

The study pharmacist interviewed the participants using the first part of the modified IMM-form described above. Then the participants filled in self-report questionnaires, as described. These were filled out by the participant in their room without the study pharmacist being
present. Participants unable to fill out the questionnaires by themselves because of paralysis, received assistance from either a personal assistant or the study pharmacist. Lastly, the study pharmacist completed the interview using the second part of the modified IMM-form and the participants also got a chance to ask questions or make comments.

The time for the interview was scheduled by the study pharmacist together with the participant, and the interview took place in the participant’s hospital room.

**Statistical analysis**

Data were analyzed using SPSS 22.0 for Windows. Association between adherence and relevant variables were tested using Chi square tests. The variables tested were age, gender, neurological level of injury, AIS grade, time since injury (years), BMQ (each subscale separately), number of regularly used drugs, and the level of spasticity (only for those using oral spasmolytic drugs). Variables as age, time since injury, number of regularly used drugs and neurological level of injury were divided into following groups to get a more uniform distribution before the analysis:

- **Age:** 21-46, 48-64, 65-87
- **Time since injury:** 1-12, 13-25, 26-55
- **Number of regularly used drugs:** 1-2, 3-5, 6-15
- **Neurological level of injury:** C1-C8, T1-T12, L1-S5

A retrospective sensitivity analysis was also performed, where the variables mentioned above were grouped following the standardization as described by Biering-Sorensen et al. (18).

**Statement of ethics**

We received ethical approval for this study from the Norwegian Regional Committee for Medical and Health Research Ethics (REC South East, case number 2015/724). We certify
that all applicable institutional and governmental regulations concerning the ethical use of
human volunteers were followed during the course of this research.

Results

Participant characteristics

From a total of 173 persons with SCI admitted for a follow-up stay during the study period,
125 persons met the inclusion criteria. Of these, 112 persons gave their consent to participate.
Further, two participants were excluded because they did not show up for the interview, two
withdrew their consent to participate and three participants were excluded after inclusion
because they did not continue to meet the inclusion criteria at the point of interview. Finally,
105 participants completed the study. The participants had a mean age of 53 years and most
were males (63%), Table 1. A total of 24 participants (23%) needed assistance in completing
the questionnaires, two of them were assisted by a personal assistant and the rest by the study
pharmacist. There were no missing answers on any of the questionnaires

Use of medicines

The participants used in average 4.2 drugs regularly (range 1-15; SD 2.8, median 4) and 1
drug on demand (range 0-5, SD 1.3, median 0). We registered a total of 440 prescriptions of
regular medicines, corresponding to 129 active pharmaceutical ingredients (API). The most
frequent APIs used, were drugs for the nervous system (ATC group N), which was used by
30% of the participants. An overview of the 10 most regularly used APIs is listed in Table 2.
A total of 66% of the participants used one or more oral drug for pain, including not only
drugs classified as analgesics (ATC-group N02), but also pregabalin, gabapentin and
amitriptyline which are APIs often used in treatment of neuropathic pain. At the time of the
interview 94% of the participants reported at least some level of pain, of which 53% reported
intense or moderate pain according to the VAS measurements.
A total of 39 participants (37%) used oral spasmolytic drugs: 35 of them used baclofen, 7 used tizanidine, and 3 participants used a combination of both. 77% of the participants reported at least some level of spasticity, 18% of these reported severe spasticity. Of drugs used on demand, 100 prescriptions were registered, corresponding to 46 various APIs, of which 63% were drugs for the nervous system (ATC-group N). An overview of the 10 most frequently used APIs on demand is listed in Table 2.

As many as 95 participants (90%) reported that they did not need assistance to take their medicines. A total of 30% (n=31) of the participants felt they lacked knowledge about their medicines, and most of them reported that they chose to trust their doctor instead of trying to gain more knowledge.

*Adherence*

Results from the MMAS-8 for all regularly used drugs and oral spasmolytic drugs are presented in Figure 1. The adherence to the regular medicines was reported to be high or moderate by 70% (n=74) of the participants, and the corresponding for oral spasmolytic drugs was 74% (n=29).

*Beliefs about medicines*

A total of 97% of the participants reported high perceptions of necessity to their treatment, while 54% reported a high level of concern. Most participants (65%) believed that medicines are generally overused and 42% believed that medicines are generally harmful. Responses to the individual items on the BMQ-Concern and BMQ-Necessity scales are presented in Figure 2.

Categorizing the participants in 4 attitudinal groups based on data from the BMQ-Concern and BMQ-Necessity subscales showed that 52% of the participants were ambivalent (high
necessity beliefs and high concerns) to their treatment while the other half was accepting, Figure 3.

Variables associated with adherence

Analysis of associations between adherence and gender, age, neurological level, AIS-score, time since injury, number of regularly used drugs, VAS, BMQ and mPSFS showed that the only statistically significant variable was age (p=0.008). In the retrospective sensitivity analysis on the other hand, using the classification by Biering-Sorensen et al. (18), age was not formally a significant variable associated with adherence (p=0.055).

Discussion

To our knowledge, this is the first study describing use of medicines and adherence among persons with chronic SCI. Our finding that the participants used in average 4.2 regular drugs is in line with other studies reporting on persons with chronic conditions using in average 3-5 regular drugs (19-21).

Only a third of the participants in our cohort used oral spasmolytic drugs regularly, even though nearly 80% of them reported at least some level of spasticity. The explanation could be that mild spasticity can have a positive impact on functionality, or the fact that the most common oral spasmolytic drugs come with undesirable side effects as sedation and dizziness (7, 22). Baclofen was the most frequently used API in our cohort which in agreement with the fact that baclofen is the most common oral spasmolytic drug used by persons with chronic SCI (23).

The finding that approximately two thirds of the patients used analgesics regularly underscore the pain challenge they have. This included pregabalin, gabapentin and amitriptyline which we chose to register as analgesics, although they are not formally classified as belonging to this ATC-group. Pregabalin, gabapentin and amitriptyline were among the ten most frequently
used APIs in this population, and are known to be the most effective drugs in the treatment of neuropathic pain among persons with SCI (24). The majority of the drugs on demand were also analgesics, with paracetamol, tramadole and codeine being the most frequently used APIs. Despite the fact that about two thirds of the participants used analgesics regularly, almost everyone (94%) reported that they experienced some level of pain at the time of the interview. The explanation could be that treatment of neuropathic pain is often difficult, and oral analgesics only give a small or moderate pain relief (24, 25).

The results show that over two thirds were highly or moderately adherent to their regular drugs, which is more than what has been found in previous studies with persons with other chronic conditions, where 11-56% of the persons had a high level of adherence (26-28). The adherence was also high for spasmolytic drugs. The high level of adherence could be explained by the seriousness of the condition or escalation of severe symptoms as pain or spasms when not following the medication regimen. The latter has been found to be associated with adherence in other studies (29). The only variable that was found to be associated with adherence was age, with younger age being associated with poorer adherence. This finding is supported by several studies with persons with other chronic conditions, suggesting that younger persons are more likely to be newly-diagnosed and therefore less familiar with and in control of their diagnosis (30). It should be acknowledged, that the small sample size in our study could explain the failure to find associations between the variables and adherence.

Although the association was significant, the finding was not formally confirmed by the retrospective sensitivity analysis using the age classification by Biering-Sorensen et al. (18). This could be explained by the low number of participants in the youngest and oldest age groups in the latter analysis.
Compared to previous studies on long-term conditions, our persons with chronic SCI score higher when it comes to believing in the necessity of their treatment. On the other side, participants in our study were more concerned about their treatment and they also believed that medicines are more harmful and that there is more overuse than what has been found previously (31-34). Some studies suggest that persons who score high on the BMQ-Concern subscale are also likely to score higher on BMQ-Harm and BMQ-Overuse subscales (30). Our findings support this theory.

This study has some limitations in addition to those noted above. Firstly, the majority of the results in this study is based on self-reported data, so we are not able to exclude reporting biases. The interview guide used in this study was not validated, only tested in five participants in a pilot study. Although MMAS-8 and BMQ are validated for several other patient groups, they have not been validated for persons with SCI. It should be mentioned that self-report questionnaires have in previous studies been associated with over-reporting of adherence (35). Further, the participants who needed assistance for completing the questionnaires may not have answered as honestly as those who completed the questionnaires by themselves.

The participants were not asked to report the indication for the drugs they were using. Therefore, it is not certain if all the medicines listed are used as a result of a SCI or because of other conditions. And lastly, it is possible the group of persons studied may not be generalizable to the whole population of persons with chronic SCI. We only included persons admitted for a voluntary follow-up stay, who might have a better insight into their condition and are more in control of their treatment compared to the rest of this population. On the other hand, some eligible persons might be too busy to participate as well. This could contribute to explaining the high levels of adherence and beliefs of necessity reported by the participants in
the present study. Thus, additional studies are required and should strive to include a broader patient population, also including post-acute injured persons.

**Conclusion**

This study indicates that persons with chronic SCI use as many regular drugs as persons with other chronic conditions. Most of the participants in our group find their medicines necessary, although the majority also had high levels of concern to their medicines. This indicates that there is need for more education and counselling, for example in forms of medicine use reviews, to make the participants feel safe about their drug regimen. Our findings also suggest that our cohort have higher overall adherence compared to other patient groups with chronic illnesses. There is need for further studies with larger population groups to understand adherence and factors determining adherence among persons with SCI.

**Acknowledgements**

The study was funded by the Hospital pharmacies enterprise, South Eastern Norway and Sunnaas Rehabilitation Hospital. We would like to thank the study participants and the nursing staff of department for follow-up at Sunnaas Rehabilitation Hospital.
References


**Titles and legends to tables and figures**

Table 1. Characteristics for the 105 participants with SCI included in the study.

Table 2. Overview of the 10 most used regular and on demand APIs expressed as number of prescriptions per API and percentage of participants using the drug.

Figure 1. A histogram of adherence results from the MMAS-8. Shows percentages of patients being “low adherent” (MMAS-8 <6), “moderate adherent” (MMAS-8 = 6-7) or “high adherent” (MMAS-8 = 8) to both regular medicines and oral spasmolytics. Y-axis shows number of participants in each category.

Figure 2. (a) Percentages of participants expressing concerns about their medicines, as indicated by responding «uncertain», «disagree» or «strongly disagree» on BMQ-Necessity items. (b) Percentages of participants expressing doubts about their medicines, as indicated by responding «agree» or «strongly agree» to BMQ-Concerns item.

Figure 3. Patients divided in attitudinal groups “accepting” (high necessity and low concern), “ambivalent” (high necessity and high concern), “indifferent” (low necessity and low concern) and “sceptical” (low necessity and high concern) based on BMQ-Concern and BMQ-Necessity results.
Adherence measured by MMAS-8

<table>
<thead>
<tr>
<th>Category</th>
<th>Number of Patients</th>
<th>Adherence to Regular Medicines</th>
<th>Adherence to Oral Spasmolytic Drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low adherence (MMAS-8 &lt; 6)</td>
<td>30</td>
<td>10</td>
<td>20</td>
</tr>
<tr>
<td>Moderate adherence (MMAS-8 = 6-7)</td>
<td>40</td>
<td>20</td>
<td>20</td>
</tr>
<tr>
<td>High adherence (MMAS-8 = 8)</td>
<td>40</td>
<td>30</td>
<td>10</td>
</tr>
</tbody>
</table>

Abbreviations: MMAS-8, Morisky Medication Adherence Scale
a
I sometimes worry about the long-term effects of my medicines.
Having to take medicines worries me.
I sometimes worry about becoming too dependent on my medicines.
My medicines cause unpleasant side effects.
My medicines are a mystery to me.
My medicines disrupt my life

% of participants responding "uncertain", "disagree" or "strongly disagree" to BMQ-Necessity statements

b
Without my medicines I would be very ill.
My life would be impossible without my medicines.
My medicines protect me from becoming worse.
My health in the future will depend on my medicines.
My health at present depends on my medicines.

% of participants responding "agree" or "strongly agree" to BMQ-Concerns statements

Abbreviations: BMQ, Beliefs about Medicines Questionnaire
Abbreviations: BMQ, Beliefs about Medicines Questionnaire
<table>
<thead>
<tr>
<th>Characteristics</th>
<th>N=105 participants</th>
<th>n</th>
<th>%</th>
<th>Mean (SD)</th>
<th>Median (range)</th>
</tr>
</thead>
</table>

**Gender**

- Male: 66, 62.8%
- Female: 39, 37.1%

**Age**

- 16-30: 11, 10.4
- 31-45: 22, 10.9
- 46-60: 34, 32.4
- 61-75: 31, 29.5
- 76+: 7, 6.7

**Years since injury**

- 19 (14), 15 (2-54)

**AIS**

- A: 24, 22.9
- B: 7, 6.7
- C: 10, 9.5
- D: 27, 25.7
- E: 0, 0
- Unknown: 37, 35.2

**Neurological category**

- C1-C4 A,B,C: 3, 2.9
- C5-C8 A,B,C: 15, 14.3
- T1-S3 A,B,C: 31, 29.5
- All AIS D: 26, 24.8
- Unknown: 30, 28.6

**Type of injury**

- Incomplete: 52, 49.5
- Complete: 38, 36.2
- Unknown: 15, 14.3

**Level of injury**

- Paraplegic: 57, 54.3
- Tetraplegic: 40, 38.1
- Unknown: 8, 7.2

**Medicines**

- Regular: 4.2 (2.8), 4 (1-15)
- On demand: 1 (1.3), 0 (0-5)

Abbreviations: AIS, American Spinal Injury Association Impairment Scale
<table>
<thead>
<tr>
<th>API</th>
<th>Prescriptions, n</th>
<th>%*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Used regularly</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baclofen (ATC group M)</td>
<td>35</td>
<td>33.3</td>
</tr>
<tr>
<td>Methenamine (ATC group J)</td>
<td>30</td>
<td>28.6</td>
</tr>
<tr>
<td>Pregabalin (ATC group N)</td>
<td>23</td>
<td>21.9</td>
</tr>
<tr>
<td>Gabapentin (ATC group N)</td>
<td>22</td>
<td>20.9</td>
</tr>
<tr>
<td>Amitriptyline (ATC group N)</td>
<td>19</td>
<td>18.1</td>
</tr>
<tr>
<td>Solifenacin (ATC group G)</td>
<td>16</td>
<td>15.4</td>
</tr>
<tr>
<td>Acetylsalicylic acid (ATC group B)</td>
<td>15</td>
<td>14.3</td>
</tr>
<tr>
<td>Paracetamol (ATC group N)</td>
<td>13</td>
<td>12.4</td>
</tr>
<tr>
<td>Furosemide (ATC group C)</td>
<td>10</td>
<td>9.5</td>
</tr>
<tr>
<td>Zopiclone (ATC group N)</td>
<td>10</td>
<td>9.5</td>
</tr>
<tr>
<td><strong>Used on demand</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paracetamol (ATC group N)</td>
<td>14</td>
<td>13.3</td>
</tr>
<tr>
<td>Tramadol (ATC group N)</td>
<td>9</td>
<td>8.6</td>
</tr>
<tr>
<td>Diazepam (ATC group N)</td>
<td>7</td>
<td>6.7</td>
</tr>
<tr>
<td>Codeine+Paracetamol (ATC group N)</td>
<td>7</td>
<td>6.7</td>
</tr>
<tr>
<td>Zopiclone (ATC group N)</td>
<td>6</td>
<td>5.7</td>
</tr>
<tr>
<td>Ibuprofen (ATC group M)</td>
<td>4</td>
<td>3.8</td>
</tr>
<tr>
<td>Oxazepam (ATC group N)</td>
<td>4</td>
<td>3.8</td>
</tr>
<tr>
<td>Oxycodone (ATC group N)</td>
<td>4</td>
<td>3.8</td>
</tr>
<tr>
<td>Diclofenac (ATC group M)</td>
<td>3</td>
<td>2.9</td>
</tr>
<tr>
<td>Ketobemidone (ATC group N)</td>
<td>2</td>
<td>1.9</td>
</tr>
</tbody>
</table>

*percent of participants using drug

Abbreviations: API, Active Pharmaceutical Ingredient; ATC, Anatomical Therapeutic Chemical classification